FTC's Androgel Case May Not Be Best To Tackle Pay-For-Delay
The Federal Trade Commission has argued that its case over the legality of pay-for-delay settlements involving blockbuster drug Androgel is a strong candidate for high court review, but with two other...To view the full article, register now.
Already a subscriber? Click here to view full article